{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-154245","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.896039+00:00","generated_at":"2026-06-14T14:39:14.370069+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Quince Therapeutics shareholders approve 1-for-10 reverse stock split and elect directors at annual meeting","bullets":["Shareholders approved 1-for-10 reverse stock split: 22.3M votes for, 4.0M against.","Margaret McLoughlin and Una Ryan elected as Class I directors with over 8.1M votes each.","Ratification of BDO USA as auditor for FY2023 approved with 22.9M votes for.","Advisory vote on executive compensation passed with 8.7M votes for, 2.3M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-154245","json":"https://secwatch.observer/filing/0001193125-23-154245.json","markdown":"https://secwatch.observer/filing/0001193125-23-154245.md","text":"https://secwatch.observer/filing/0001193125-23-154245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523154245/0001193125-23-154245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523154245/d367319d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:39:14.370069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6040947ddd5cc32857149967c514ad50054e8b60","claim":"Quince Therapeutics, Inc. shareholders approved Election of two Class I directors at the 2023-05-24 meeting.","evidence_excerpt":"The Company’s stockholders approved the election of two Class I directors to the Board of Directors for three year terms or until their respective successors are duly elected and qualified or until their earlier death, resignation, disqualification or removal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523154245/0001193125-23-154245-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-24"}],"fact_type":"shareholder_vote"},{"claim_id":"a13fff41aaef32ff2199284c761d4fc22e3f5790","claim":"Quince Therapeutics, Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm BDO USA, LLP at the 2023-05-24 meeting.","evidence_excerpt":"The Company’s stockholders ratified the selection of BDO USA, LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523154245/0001193125-23-154245-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-24"}],"fact_type":"shareholder_vote"},{"claim_id":"c5650144448ba5ffc965c9f618560978555630c0","claim":"Quince Therapeutics, Inc. shareholders approved Advisory approval of the compensation of the Company's named executive officers at the 2023-05-24 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523154245/0001193125-23-154245-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-24"}],"fact_type":"shareholder_vote"},{"claim_id":"cf7be54193d3b3676c635adb609eb939cccbb77d","claim":"Quince Therapeutics, Inc. shareholders approved Approval of Amendment to the Certificate of Incorporation to Effect a Reverse Stock Split at a ratio of one-for-ten at the 2023-05-24 meeting.","evidence_excerpt":"The Company’s stockholders approved the amendment to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding common stock at a ratio of one-for-ten.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523154245/0001193125-23-154245-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-24"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}